SABSW · As filed with the SEC
SAB Biotherapeutics income statement, by fiscal year
The statement as SAB Biotherapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations and Comprehensive Income (Loss) · USD, except per-share amounts
| USD, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 |
|---|---|---|
| Revenue | ||
| Total revenue | 0 | 1,322,410 |
| Research and development | 34,352,332 | 30,251,667 |
| General and administrative | 14,601,031 | 13,981,263 |
| Total operating expenses | 48,953,363 | 44,232,930 |
| Loss from operations | (48,953,363) | (42,910,520) |
| Changes in fair value of warrant liabilities | 62,754,186 | 5,385,009 |
| Interest expense | (240,664) | (318,401) |
| Interest income | 1,432,032 | 1,285,998 |
| Other income | 3,133,784 | 2,452,605 |
| Warrant issuance expense | (4,852,292) | 0 |
| Total other income | 62,227,046 | 8,805,211 |
| Net income (loss) | 13,273,683 | (34,105,309) |
| Other comprehensive income (loss): | ||
| Unrealized gain, change in fair value of available-for-sale securities, net of tax | 185,464 | 647 |
| Foreign currency translation gain (loss) | 136,456 | (162,477) |
| Total comprehensive income (loss) | 13,595,603 | (34,267,139) |
| Income (loss) per common share attributable to the Company's shareholders | ||
| Basic income (loss) per common share | 0.22 | (3.68) |
| Diluted loss per common share | (0.79) | (3.68) |
| Weighted-average common shares outstanding - basic | 19,311,798 | 9,261,918 |
| Weighted-average common shares outstanding - diluted | 61,340,193 | 9,261,918 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.